Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market

Aligos Therapeutics, Inc. (ALGS) announced an update on their ongoing clinical study.

Aligos Therapeutics Advances Phase 1 Study of Pevifoscorvir Sodium in Liver-Impaired Patients and Healthy Volunteers

The study, titled “A Phase 1 Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function,” aims to see how the drug behaves in the body and how safe it is in people with moderate liver problems versus healthy volunteers. The focus is on understanding dosing and safety in chronic hepatitis B, a large global market, which makes this early study an important building block for Aligos Therapeutics’ pipeline.

The treatment being tested is pevifoscorvir sodium (ALG-000184), an oral drug candidate given as a single 100 mg dose. It is designed to help treat chronic hepatitis B by targeting the virus in the liver, with this study checking how the drug is processed in people with and without liver impairment and whether it is well tolerated.

This is an interventional Phase 1 trial. It is non-randomized, so participants are assigned to groups ahead of time, not by chance. There are two parallel groups: eight subjects with moderate liver impairment and eight healthy subjects. Both groups receive the same single oral dose and are followed for 14 days. The trial is open-label, meaning both doctors and participants know what is given, and there is no placebo. The main goal is treatment-focused: to guide future dosing and safety work in patients with liver disease.

The trial is listed as not yet recruiting. The study was first submitted on December 15, 2025, signaling the sponsor’s intent to move this program forward. The most recent update was submitted on January 14, 2026, which shows the protocol is current and still active. Primary completion and overall completion dates have not yet been reported, so investors should assume data readouts are still some time away and will follow once dosing and follow-up are finished.

For investors, this update reinforces that Aligos continues to invest in its hepatitis B portfolio, with pevifoscorvir sodium moving into a more refined safety and dosing phase in a higher-risk population. While Phase 1 hepatic impairment studies rarely move a stock on their own, they are a necessary step toward later-stage trials and eventual regulatory filings. The broader HBV field includes players like Gilead, Vir Biotechnology, and Janssen, and any positive safety and drug-exposure data could support Aligos’ positioning as a niche but credible competitor. Near term, sentiment may improve on evidence of steady execution and a clear clinical plan, but major valuation shifts are more likely tied to later efficacy data and partnering moves.

The study is currently ongoing in its setup phase and has been recently updated, with further details available on the ClinicalTrials.gov portal.

To learn more about ALGS’s potential, visit the Aligos Therapeutics, Inc. drug pipeline page.